• Relay Medical (RELA) is retaining Emerging Markets Consulting to provide investor relations advisory services
  • Emerging Markets Consulting specializes in helping small and mid-sized public companies establish brand awareness
  • It also helps increase market share to its customer base while improving visibility to the institutional and retail investment community
  • Relay Medical is down 6.17 per cent on the day, with shares trading at C$0.38 at 3:44 pm ET

Relay Medical (RELA) is retaining Emerging Markets Consulting to provide investor relations advisory services.

Emerging Markets Consulting specializes in helping small and mid-sized public companies establish brand awareness and increase market share to its customer base while improving visibility to the institutional and retail investment community.

“With the recent deployments of Toronto Airport and partnering with Canada’s largest lab company Lifelabs, Relay has a lot to share with the marketplace. We look forward to working with Emerging Markets to bring Relay to a broader audience and build on our communication as we progress through these milestones and others like the recent acquisition of Cybeats, an innovative IoT Cybersecurity company,” said Relay Medical President W. Clark Kent.

“With the termotulous year we have all faced, hope springs eternal. Working with Relay Medical is an honor and a privilege. The company’s prospects met our stringent requirements and we are happy to have Relay on our prestigious client roster,” said EMC President James Painter.

Relay Medical is a Canadian-based technology innovation company focused on the development of novel technologies in the diagnostics and AI data science and IoT security sectors.

Relay Medical is down 6.17 per cent on the day, with shares trading at C$0.38 at 3:44 pm ET.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.